EP3520780C0 - Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer mittel - Google Patents

Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer mittel

Info

Publication number
EP3520780C0
EP3520780C0 EP19161397.5A EP19161397A EP3520780C0 EP 3520780 C0 EP3520780 C0 EP 3520780C0 EP 19161397 A EP19161397 A EP 19161397A EP 3520780 C0 EP3520780 C0 EP 3520780C0
Authority
EP
European Patent Office
Prior art keywords
vehicles
pharmaceutical agents
different pharmaceutical
controlled administration
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19161397.5A
Other languages
English (en)
French (fr)
Other versions
EP3520780A1 (de
EP3520780B1 (de
Inventor
Tarek M Fahmy
Eric Stern
Richard A Flavell
Jason Park
Alyssa Siefert
Stephen H Wrzesinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to EP21192661.3A priority Critical patent/EP3939572B1/de
Publication of EP3520780A1 publication Critical patent/EP3520780A1/de
Application granted granted Critical
Publication of EP3520780C0 publication Critical patent/EP3520780C0/de
Publication of EP3520780B1 publication Critical patent/EP3520780B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
EP19161397.5A 2012-04-12 2013-04-12 Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer mittel Active EP3520780B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21192661.3A EP3939572B1 (de) 2012-04-12 2013-04-12 Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer wirkstoffe

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623486P 2012-04-12 2012-04-12
US201261747614P 2012-12-31 2012-12-31
US201261747624P 2012-12-31 2012-12-31
EP13718738.1A EP2836234B1 (de) 2012-04-12 2013-04-12 Vehikel zur kontrollierten abgabe verschiedener pharmazeutischer substanzen
PCT/US2013/036487 WO2013155487A1 (en) 2012-04-12 2013-04-12 Vehicles for controlled delivery of different pharmaceutical agents

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP13718738.1A Division EP2836234B1 (de) 2012-04-12 2013-04-12 Vehikel zur kontrollierten abgabe verschiedener pharmazeutischer substanzen
EP13718738.1A Division-Into EP2836234B1 (de) 2012-04-12 2013-04-12 Vehikel zur kontrollierten abgabe verschiedener pharmazeutischer substanzen

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP21192661.3A Division EP3939572B1 (de) 2012-04-12 2013-04-12 Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer wirkstoffe
EP21192661.3A Division-Into EP3939572B1 (de) 2012-04-12 2013-04-12 Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer wirkstoffe

Publications (3)

Publication Number Publication Date
EP3520780A1 EP3520780A1 (de) 2019-08-07
EP3520780C0 true EP3520780C0 (de) 2023-07-26
EP3520780B1 EP3520780B1 (de) 2023-07-26

Family

ID=48184518

Family Applications (3)

Application Number Title Priority Date Filing Date
EP19161397.5A Active EP3520780B1 (de) 2012-04-12 2013-04-12 Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer mittel
EP13718738.1A Active EP2836234B1 (de) 2012-04-12 2013-04-12 Vehikel zur kontrollierten abgabe verschiedener pharmazeutischer substanzen
EP21192661.3A Active EP3939572B1 (de) 2012-04-12 2013-04-12 Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer wirkstoffe

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP13718738.1A Active EP2836234B1 (de) 2012-04-12 2013-04-12 Vehikel zur kontrollierten abgabe verschiedener pharmazeutischer substanzen
EP21192661.3A Active EP3939572B1 (de) 2012-04-12 2013-04-12 Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer wirkstoffe

Country Status (7)

Country Link
US (9) US9603800B2 (de)
EP (3) EP3520780B1 (de)
JP (5) JP6378170B2 (de)
CA (1) CA2869748C (de)
ES (1) ES2745211T3 (de)
PL (1) PL2836234T3 (de)
WO (2) WO2013155493A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9475709B2 (en) 2010-08-25 2016-10-25 Lockheed Martin Corporation Perforated graphene deionization or desalination
EP2622064B1 (de) 2010-10-01 2019-05-29 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (de) 2011-10-03 2020-03-04 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2836234T3 (pl) 2012-04-12 2020-02-28 Yale University Podłoża do kontrolowanego dostarczania różnych środków farmaceutycznych
EP2841098A4 (de) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanopartikel zur behandlung von allergien
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US10500546B2 (en) 2014-01-31 2019-12-10 Lockheed Martin Corporation Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US10696554B2 (en) 2015-08-06 2020-06-30 Lockheed Martin Corporation Nanoparticle modification and perforation of graphene
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
CA2896537C (en) * 2013-01-08 2021-10-12 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
JP6464103B2 (ja) * 2013-03-11 2019-02-06 クリスタル・デリバリー・ビー・ブイ ワクチン接種用組成物
TW201504140A (zh) 2013-03-12 2015-02-01 Lockheed Corp 形成具有均勻孔尺寸之多孔石墨烯之方法
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX375502B (es) 2013-04-03 2025-03-04 N Fold Llc Composiciones de nanoparticulas novedosas.
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
AU2014342004B2 (en) 2013-11-01 2017-10-26 Yale University Modular particles for immunotherapy
CA2938273A1 (en) 2014-01-31 2015-08-06 Peter V. Bedworth Perforating two-dimensional materials using broad ion field
CA2942496A1 (en) 2014-03-12 2015-09-17 Lockheed Martin Corporation Separation membranes formed from perforated graphene
US20170216401A1 (en) * 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
US10739338B2 (en) 2014-03-24 2020-08-11 Qt Holdings Corp Shaped articles including hydrogels and methods of manufacture and use thereof
WO2015148971A2 (en) 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
JP6776223B2 (ja) 2014-04-01 2020-10-28 チルドレンズ ホスピタル ロサンゼルス 癌治療のためのターゲティングされた重合ナノ粒子
US9956176B2 (en) 2014-04-01 2018-05-01 Children's Hospital Los Angeles Compositions and methods for treating ewing sarcoma
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
CN107073408A (zh) 2014-09-02 2017-08-18 洛克希德马丁公司 基于二维膜材料的血液透析膜和血液过滤膜及其应用方法
US20180008629A1 (en) * 2015-01-29 2018-01-11 Yale University Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
CN104735414B (zh) * 2015-03-25 2017-11-28 江苏物联网研究发展中心 面向视频监控系统的半实物仿真方法
JP6522387B2 (ja) * 2015-03-27 2019-05-29 株式会社キレートジャパン ハイドロゲル含有化粧料
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
BR112017025422A2 (pt) * 2015-05-27 2018-08-07 Univ Northwestern partículas modificadas por carboidrato e formulações particuladas para modular uma resposta imune
CA2988593C (en) 2015-06-16 2023-10-24 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
AU2016281685B2 (en) 2015-06-24 2021-08-12 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
CA2994549A1 (en) 2015-08-05 2017-02-09 Lockheed Martin Corporation Perforatable sheets of graphene-based material
US10626469B2 (en) 2015-09-04 2020-04-21 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Rapid identification of microorganisms
EP3350157B1 (de) 2015-09-17 2022-01-05 Modernatx, Inc. Verbindungen und zusammensetzungen zur intrazellulären verabreichung von therapeutischen wirkstoffen
US9790467B2 (en) 2015-09-22 2017-10-17 Qt Holdings Corp Methods and compositions for activation or expansion of T lymphocytes
RU2768936C2 (ru) * 2015-10-07 2022-03-25 Джоэль УЙСЕНГА Нормализация функций биологических путей для защиты от и устранения нарушений, возникающих вследствие старения человека
ES2913626T5 (en) 2015-12-22 2025-05-12 Modernatx Inc Compounds and compositions for intracellular delivery of agents
WO2017180133A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Methods for in situ monitoring and control of defect formation or healing
KR20190018410A (ko) 2016-04-14 2019-02-22 록히드 마틴 코포레이션 흐름 통로들을 갖는 2차원 막 구조들
JP2019521055A (ja) 2016-04-14 2019-07-25 ロッキード・マーチン・コーポレーション グラフェン欠陥の選択的界面緩和
WO2017180134A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
CA3020686A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Method for treating graphene sheets for large-scale transfer using free-float method
IL319503A (en) * 2016-05-16 2025-05-01 Access To Advanced Health Inst PEGylated liposomes and methods of use
EP3251662A1 (de) * 2016-06-07 2017-12-06 Tolerogenics S.à.r.l. In eine matrix eingebettete toleranzförderungsadjuvantien zur subkutanen immuntherapie
CN109476841B (zh) * 2016-07-30 2021-08-24 日本化药株式会社 新型高分子衍生物和使用其的新型高分子衍生物成像探针
WO2018051298A1 (en) * 2016-09-19 2018-03-22 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
WO2018085407A1 (en) * 2016-11-02 2018-05-11 Nanoproteagen Polymeric nanoparticles
EP3538067A1 (de) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilisierte formulierungen von lipidnanopartikeln
ES2968358T3 (es) * 2016-12-26 2024-05-09 Fujifilm Corp Composición de partículas lipídicas y composición farmacéutica
JP7220154B2 (ja) 2017-03-15 2023-02-09 モデルナティエックス インコーポレイテッド アミノ脂質の結晶形態
EP3595727B1 (de) 2017-03-15 2024-11-27 ModernaTX, Inc. Lipidnanopartikelformulierung
PL3596041T3 (pl) 2017-03-15 2023-03-06 Modernatx, Inc. Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych
EP3595636A4 (de) 2017-03-16 2021-01-13 Children's Medical Center Corporation Gentechnisch hergestellte liposomen als zielgerichtete therapeutika gegen krebs
US11491247B2 (en) 2017-05-02 2022-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
JP6482604B2 (ja) * 2017-06-22 2019-03-13 教裕 南郷 外皮内溶解型ニードル及びニードル装置
WO2019005966A1 (en) 2017-06-29 2019-01-03 Massachusetts Institute Of Technology CONJUGATED DRUG DENDRIMER FOR EXTENDED INTRA-ARTICULAR ADMINISTRATION
WO2019006371A1 (en) * 2017-06-30 2019-01-03 City Of Hope COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2019070890A1 (en) * 2017-10-03 2019-04-11 Northwestern University SPHERICAL NUCLEIC ACIDS (SNAs) WITH PEG LAYERS THAT CAN BE REMOVED
CN111278477A (zh) * 2017-10-25 2020-06-12 精密医疗国际公司 生物降解性和生物代谢性的肿瘤封闭剂
CN118420783A (zh) * 2017-12-06 2024-08-02 恺兴生命科技(上海)有限公司 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
WO2020256722A1 (en) * 2019-06-19 2020-12-24 Becton, Dickenson And Company Biodegradable drug-eluting embolic particles for delivery of therapeutic agents
CN111801024A (zh) * 2018-01-04 2020-10-20 麻省理工学院 具有肠溶性聚合物屏障的水溶性和脂溶性微量营养素稳定的颗粒
US12194103B2 (en) 2018-03-23 2025-01-14 University Of Washington Immunosuppressive materials and related methods
KR102153535B1 (ko) * 2018-03-30 2020-09-08 한국과학기술원 동맥경화증 치료를 위한 화물치환 분해성 나노바이오소재
AU2019265632A1 (en) * 2018-05-09 2021-01-07 Yale University Particles for spatiotemporal release of agents
WO2020014208A1 (en) 2018-07-09 2020-01-16 Yale University Camk4 inhibitors for restoration of podocyte function in kidney disease
CA3113436A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
US11680243B2 (en) * 2019-02-20 2023-06-20 Iowa State University Research Foundation, Inc. Conductive graphene matrix-encapsulated cells
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
CN110393700A (zh) * 2019-04-02 2019-11-01 武汉理工大学 F3多肽导向的pamam为核心的肿瘤药物纳米载体的制备与应用
CN109916896A (zh) * 2019-04-12 2019-06-21 吉林省汇酉生物技术股份有限公司 一种定量检测血红蛋白含量的干化学试剂片及其制备方法
US20220249696A1 (en) * 2019-04-12 2022-08-11 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
CN114072163A (zh) * 2019-05-09 2022-02-18 芝加哥大学 皮肤伤口愈合和瘢痕预防的新材料
EP3972572A4 (de) 2019-05-20 2023-11-22 Board Of Regents Of the University Of Texas System Formulierungen von nanopartikeln auf der basis von cyclischen makromolekülen, die kleine moleküle verkapseln
KR20220101077A (ko) 2019-09-19 2022-07-19 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 분지형 꼬리 지질 화합물 및 조성물
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
US20220395563A1 (en) * 2019-11-11 2022-12-15 The Regents Of The University Of California Polymeric nanoparticles that target liver sinusoidal endothelial cells to induce antigen-specific immune tolerance
CN115335041A (zh) 2019-12-05 2022-11-11 西弗吉尼亚大学 负载有蛋白质的plga纳米球
KR20220154740A (ko) * 2020-03-17 2022-11-22 제네반트 사이언시즈 게엠베하 간 성상 세포로 치료제의 지질 나노입자 전달을 위한 양이온성 지질
JP2023522015A (ja) 2020-04-17 2023-05-26 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク サルコペニアを逆行させる方法、組成物及びその使用
CN111450094A (zh) * 2020-05-06 2020-07-28 南开大学 一种TGF-beta受体分子抑制剂在癌基因KrasG12D突变的胰腺癌治疗中的应用
CN114108177B (zh) * 2020-08-28 2022-12-27 北京化工大学 一种可光热触发生长因子阶段性释放的人工皮肤材料及其制法和应用
KR20230079127A (ko) * 2020-10-01 2023-06-05 스탠다드 밀록스 파마슈티컬스 오와이 하이드로겔 물질
IT202100002537A1 (it) * 2021-02-05 2022-08-05 Kyme Nanoimaging Srl Processo microfluidico per la preparazione di nanostrutture liposomiche caricate con idrogel
CN113908138A (zh) * 2021-09-08 2022-01-11 四川大学华西医院 一种神经胶质瘤抗体药物组合物及制备方法
JP2024537543A (ja) * 2021-10-11 2024-10-10 ニューイミューン ザ セカンド，エルエルシー ナノ粒子製剤
GB202201351D0 (en) 2022-02-02 2022-03-16 Activate Therapeutics Llc Nanoparticulate formulation
WO2023062353A1 (en) * 2021-10-11 2023-04-20 Newimmune Ii, Llc Nanoparticulate formulation
CN113926427B (zh) * 2021-10-16 2024-07-19 济南产研国能中碳环保技术有限公司 一种用于捕集空气中二氧化碳的改性石墨烯膜及其制备方法
US20250064921A1 (en) * 2021-12-28 2025-02-27 Cz Biohub Sf, Llc Chemically modified bacterial peptidoglycan compositions and uses thereof
WO2023136248A1 (ja) 2022-01-12 2023-07-20 Ａｇｃ株式会社 樹脂組成物、成形体、複合体およびその用途
KR102626722B1 (ko) * 2022-08-04 2024-01-22 서울대학교산학협력단 나노카테난 구조체 및 나노카테난 구조체를 포함하는 나노머신
IT202200022041A1 (it) * 2022-10-25 2024-04-25 Kyme Nanoimaging Srl Nanostrutture liposomiche caricate con idrogel
US20240181139A1 (en) * 2022-12-06 2024-06-06 Pramand LLC Chemical tissue ablation with hydrogel matrix and corresponding medical applications
WO2024192233A2 (en) * 2023-03-14 2024-09-19 The Trustees Of The University Of Pennsylvania Targeted delivery of therapeutic agents to the central nervous system and methods of use for treatment of neurological conditions
CN118680868A (zh) * 2023-03-24 2024-09-24 清华大学 一种核酸药物递送系统及其制备和应用
US20250242050A1 (en) * 2024-01-31 2025-07-31 The Industry & Academic Cooperation In Chungnam National University (Iac) Composition for treating gout containing cyclodextrin-conjugated polymer nano-drug and method for treating gout
CN119857083A (zh) * 2024-12-30 2025-04-22 华西精准医学产业创新中心有限公司 疏水性黄酮类活性分子的载药微球及其制备方法和用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
US5354867A (en) 1988-12-06 1994-10-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
PH30923A (en) 1992-03-30 1997-12-23 American Home Prod Rapamycin formulation for iv injection.
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
ATE191218T1 (de) 1993-12-17 2000-04-15 Novartis Ag Rapamycin-derivate als immunosuppressoren
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
WO2001033522A1 (en) 1999-11-05 2001-05-10 American Express Travel Related Services Company, Inc. Systems and methods for facilitating commercial transactions between parties residing at remote locations
US7618565B2 (en) * 2001-08-16 2009-11-17 Polytechnic Institute Of New York University Lipobeads and their production
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7785578B2 (en) * 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
FR2849040A1 (fr) 2002-12-18 2004-06-25 Arandi Pharma Polypeptides a activite antivirale
EP1576014B1 (de) 2002-12-23 2011-06-29 Wyeth LLC Antikörper gegen pd-1 und ihre verwendung
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
EP2161336B2 (de) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Humane monoklonale Antikörper für den programmierten Tod 1 (PD-1) und Verfahren zur Behandlung von Krebs mit PD-1-Antikörpern allein oder in Kombination mit anderen Immunotherapeutika
NZ590308A (en) 2005-06-08 2012-02-24 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of cancer by inhibiting the programmed cell death 1 (pd-1) pathway
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
US20070014845A1 (en) * 2005-07-01 2007-01-18 Yuanpeng Zhang Liposomal delivery vehicle for hydrophobic drugs
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US20070243184A1 (en) 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CN101341516A (zh) 2005-12-20 2009-01-07 皇家飞利浦电子股份有限公司 用于图像数据运动补偿的方法
JP2008053276A (ja) 2006-08-22 2008-03-06 Nec Electronics Corp 半導体装置の製造方法
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2184355A4 (de) 2007-08-09 2011-04-27 Daiichi Sankyo Co Ltd Mit einem hydrophoben molekül modifizierter antikörper
EP2224958A2 (de) 2007-11-30 2010-09-08 Bristol-Myers Squibb Company Anti-b7h4 monoklonales antikörper-arzneimittel-konjugat und anwendungsverfahren
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
WO2010083337A2 (en) 2009-01-15 2010-07-22 The Regents Of The University Of Califorinia Composite nanostructures and methods for making and using them
AU2010312078B2 (en) 2009-10-26 2015-10-08 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
US20110293690A1 (en) 2010-05-27 2011-12-01 Tyco Healthcare Group Lp Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof
AU2011279024A1 (en) 2010-07-16 2013-02-21 The Johns Hopkins University Methods and compositions for cancer immunotherapy
EP2640359A4 (de) 2010-11-18 2015-11-04 Gen Hospital Corp Neue zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie
AU2012347557A1 (en) 2011-12-09 2014-07-03 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same
PL2836234T3 (pl) 2012-04-12 2020-02-28 Yale University Podłoża do kontrolowanego dostarczania różnych środków farmaceutycznych
AU2014342004B2 (en) 2013-11-01 2017-10-26 Yale University Modular particles for immunotherapy

Also Published As

Publication number Publication date
WO2013155487A1 (en) 2013-10-17
JP6608996B2 (ja) 2019-11-20
US11173119B2 (en) 2021-11-16
JP2019196410A (ja) 2019-11-14
EP3520780A1 (de) 2019-08-07
WO2013155493A1 (en) 2013-10-17
CA2869748A1 (en) 2013-10-17
US20150118318A1 (en) 2015-04-30
EP3939572B1 (de) 2024-03-27
EP3939572C0 (de) 2024-03-27
US20180369333A1 (en) 2018-12-27
US20220031617A1 (en) 2022-02-03
US10195144B2 (en) 2019-02-05
EP3939572A1 (de) 2022-01-19
US20200179283A1 (en) 2020-06-11
JP7291967B2 (ja) 2023-06-16
US20170224617A1 (en) 2017-08-10
US10709664B2 (en) 2020-07-14
US20150064265A1 (en) 2015-03-05
JP2018115219A (ja) 2018-07-26
EP2836234B1 (de) 2019-06-12
WO2013155493A9 (en) 2013-11-28
CA2869748C (en) 2017-10-24
US10034917B2 (en) 2018-07-31
US9610250B2 (en) 2017-04-04
US10500157B2 (en) 2019-12-10
EP3520780B1 (de) 2023-07-26
ES2745211T3 (es) 2020-02-28
PL2836234T3 (pl) 2020-02-28
EP2836234A1 (de) 2015-02-18
HK1206634A1 (en) 2016-01-15
US9603800B2 (en) 2017-03-28
US20190209474A1 (en) 2019-07-11
JP2022003102A (ja) 2022-01-11
JP2015512950A (ja) 2015-04-30
US10603276B2 (en) 2020-03-31
US12156939B2 (en) 2024-12-03
US20160361265A1 (en) 2016-12-15
JP6378170B2 (ja) 2018-08-22
US20180200336A1 (en) 2018-07-19
JP2021138771A (ja) 2021-09-16

Similar Documents

Publication Publication Date Title
EP3939572C0 (de) Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer wirkstoffe
EP3334499A4 (de) Bioaktive konjugaten zur freisetzung von oligonukleotiden
EP2895526A4 (de) Verzweigte polyamine zur freisetzung von biologischen wirkstoffen
EP2925395A4 (de) Verfahren und vorrichtungen zur ausgabe einer verbindung
EP2896022A4 (de) Arzneimittelabgaberegler
EP2906202A4 (de) Orale wirkstofffreisetzungsformulierungen
EP2849567A4 (de) Träger zur verbesserten arzneimittelabgabe
EP2688636A4 (de) System zur gesteuerten freisetzung medizinischer fluide
EP4134116C0 (de) Sicherheitsfunktion für eine arzneimittelabgabevorrichtung
EP3280421A4 (de) Pharmazeutische zusammensetzungen für eine kombinationstherapie
EP2544768A4 (de) Mittel zur verabreichung von krebsheilmitteln mit verbesserter ladung
EP2968071A4 (de) Vorrichtung zur oralen freisetzung von therapeutischen verbindungen
EP2968753A4 (de) Abgewinkelter inserter für eine arzneimittelinfusion
MA48050A (fr) Lipides biodégradables pour l'administration d'acides nucléiques
EP2897522A4 (de) Physiologisches mapping für arrhythmie
EP2869784A4 (de) Orale vorrichtung zur abgabe eines medikaments
EP2814486A4 (de) Antivirale mittel zur behandlung von arenavirus-infektionen
EP2844346A4 (de) Pharmazeutische zusammensetzungen für eine kombinationstherapie
EP2849770A4 (de) Pharmazeutische zusammensetzungen zur abgabe von im wesentlichen wasserunlöslichen arzneimitteln
EP2964224A4 (de) Polymerkonjugat zur verabreichung eines bioaktiven wirkstoffs
EP2552417A4 (de) Pharmazeutische formulierungen zur behandlung von blasenhyperaktivität
EP2666475A4 (de) Therapeutischer wirkstoff gegen haarausfall
FR2988609B1 (fr) Formulation pour l'hormonotherapie
EP3573614C0 (de) Pharmazeutische zusammensetzungen für eine kombinationstherapie
EP2981258A4 (de) Pharmazeutische formulierungen zur subkutanen verabreichung von furosemid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190307

AC Divisional application: reference to earlier application

Ref document number: 2836234

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PARK,, JASON

Inventor name: WRZESINSKI,, STEPHEN H

Inventor name: FLAVELL,, RICHARD A

Inventor name: STERN,, ERIC

Inventor name: FAHMY, TAREK M

Inventor name: SIEFERT,, ALYSSA

111L Licence recorded

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Name of requester: MODULATE THERAPEUTICS INC, CA

Effective date: 20200501

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210318

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230222

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WRZESINSKI, STEPHEN H

Inventor name: SIEFERT, ALYSSA

Inventor name: PARK, JASON

Inventor name: FLAVELL, RICHARD A

Inventor name: STERN, ERIC

Inventor name: FAHMY, TAREK M

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

111L Licence recorded

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Name of requester: MODULATE THERAPEUTICS INC, CA

Effective date: 20200501

AC Divisional application: reference to earlier application

Ref document number: 2836234

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013084344

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20230727

P04 Withdrawal of opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230728

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20230802

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231026

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231126

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013084344

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 12

Effective date: 20240429

26N No opposition filed

Effective date: 20240429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

P05 Withdrawal of opt-out of the competence of the unified patent court (upc) changed

Free format text: CASE NUMBER: APP_557171/2023

Effective date: 20230802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240412

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 13

Effective date: 20250428

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250428

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130412

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130412